<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00563602</url>
  </required_header>
  <id_info>
    <org_study_id>CONHEMO-2006</org_study_id>
    <secondary_id>EudraCT 2007-002237-37</secondary_id>
    <nct_id>NCT00563602</nct_id>
  </id_info>
  <brief_title>Treatment for Prevention of Variceal Rebleeding Guided by the Hemodynamic Response</brief_title>
  <official_title>Randomized and Controlled Study of Endoscopic Ligation, Nadolol and Isosorbide Mononitrate vs Endoscopic Ligation and Nadolol Alone, or Associated With Isosorbide Mononitrate or Prazosin, Depending of the Hemodinamyc Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective trial of random distribution, open, parallel group, in which patients&#xD;
      with esophagic variceal bleeding will be randomized into two treatment groups, after&#xD;
      controlling acute bleeding. All patients received standard medical therapy with b-blockers&#xD;
      and endoscopic ligation (LEV) of esophageal varices.&#xD;
&#xD;
      The control group will be assigned to receive LEV + Nadolol + MNI. The experimental group&#xD;
      will be assigned to receive treatment according to the hemodynamic response.&#xD;
&#xD;
      All patients included in the experimental group received LEV and pharmacological treatment&#xD;
      nadolol alone or combined with MNI or Prazosin (PZ)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective trial of random distribution, open, parallel group, in which patients&#xD;
      with esophagic variceal bleeding will be randomized into two treatment groups, after&#xD;
      controlling acute bleeding. All patients received standard medical therapy with b-blockers&#xD;
      and endoscopic ligation (LEV) of esophageal varices.&#xD;
&#xD;
      The control group will be assigned to receive LEV + Nadolol (N) + Isosorbide Mononitrate&#xD;
      (MNI) The experimental group will be assigned to receive treatment according to the&#xD;
      hemodynamic response.&#xD;
&#xD;
      All patients included in the experimental group received LEV and pharmacological treatment&#xD;
      nadolol alone or combined with MNI or Prazosin (PZ)&#xD;
&#xD;
      A hepatic hemodynamic study will be performed to patients in both groups, at baseline (In&#xD;
      which basal values and acute b-blockers response will be assessed), and a second study at the&#xD;
      3 rd -4 th week after the drug therapy start, after the titration of the doses.&#xD;
&#xD;
      In the experimental group, responders to the acute administration of b-blockers will receive&#xD;
      LEV + Nadolol alone, and those patients with no response will receive LEV + N + MNI, and&#xD;
      another hemodynamic study will be performed 3 rd -4 th week after the drug therapy start,&#xD;
      after the titration of the doses, to assess response. The non-responders in this control&#xD;
      study will switched to LEV+ N + PZ, and a 3erd hemodynamic study will be performed.&#xD;
&#xD;
      Randomization will be stratified according to the degree of hepatic insufficiency, assessed&#xD;
      by the Child-Pugh classification (classes A and B vs C)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2007</start_date>
  <completion_date type="Anticipated">November 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rebleeding</measure>
    <time_frame>1-2 Years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>1-2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>1-2 Years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Portal Hypertension</condition>
  <condition>Complications of Cirrhosis</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard Therapy: Endoscopic ligation (LEV) + Nadolol + Isosorbide mononitrate (MNI)(drugs carefully titrated until achieve maximum tolerated dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hemodynamic guided therapy:&#xD;
1) LEV + Nadolol. HVPG measurement: if response, no changes, if not, switch to 2) LEV + Nadolol + MNI. HVPG measurement: if response, no changes, if not, switch to: 3) LEV + Nadolol + Prazosin. (drugs carefully titrated until achieve maximum tolerated dose)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hemodynamic guided therapy</intervention_name>
    <description>To switch two or more different treatments for the prevention of variceal rebleeding according to the hemodynamic response. All patients in the experimental group will begin by:&#xD;
1) LEV + Nadolol. HVPG measurement: if response, no changes, if not, switch to 2) LEV + Nadolol + MNI. HVPG measurement: if response, no changes, if not, switch to: 3) LEV + Nadolol + Prazosin. (drugs carefully titrated until achieve maximum tolerated dose)</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All the patients admitted in emergencies in which 1) with gastrointestinal bleeding&#xD;
             due to esophageal varices assessed by endoscopy, will be included.&#xD;
&#xD;
          -  We define esophagic variceal bleeding as the endoscopic finding of any the following&#xD;
             signs: 1) active variceal bleeding 2) clot or platelet cluster or 3 ) esophageal&#xD;
             varices associated to red blood in esophagogastric lumen in the absence of other&#xD;
             sources of bleeding.&#xD;
&#xD;
          -  Clinical criteria and / or analytical, ultrasound and / or liver biopsy consistent&#xD;
             with the diagnosis of liver cirrhosis.&#xD;
&#xD;
          -  Written informed consent to participate in the study.&#xD;
&#xD;
          -  Patients in fertile age should use barrier methods to prevent pregnancy during the&#xD;
             entire study. The pregnancy test prior to the study must be negative&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 or&gt; 80 years.&#xD;
&#xD;
          -  Patients not eligible for active treatment due to any underlying morbid condition&#xD;
             (terminals). Here are included those patients with advanced liver disfunction&#xD;
             (Child-Pugh &gt;) or any patient with life expectancy &lt; 6 mo.&#xD;
&#xD;
          -  Refuse to participate in the study.&#xD;
&#xD;
          -  Bleeding due to causes other than the esophageal varices.&#xD;
&#xD;
          -  Prior inclusion in this study.&#xD;
&#xD;
          -  Failure in the control of the acute bleeding (index episode).&#xD;
&#xD;
          -  Pretreatment through elective LEV program, sclerotherapy or combined β- blockers plus&#xD;
             nitrates, or portosystemic shunt (surgical or percutaneous).&#xD;
&#xD;
          -  Contraindication for β- blockers and MNI (not exclude patients with contraindication&#xD;
             for one of these drugs) or endoscopic procedures.&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Presence multiple hepatocellular carcinoma or only diameter &gt; 5 cm.&#xD;
&#xD;
          -  Portal vein thrombosis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Candid Villanueva, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Candid Villanueva, MD</last_name>
    <phone>+34620955006</phone>
    <email>cvillanueva@santpau.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jordi Virgili</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HospitalSCSP</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Candid Villanueva, MD</last_name>
      <phone>+34620955006</phone>
      <email>cvillanueva@santpau.es</email>
    </contact>
    <investigator>
      <last_name>Candid Villanueva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <study_first_submitted>November 21, 2007</study_first_submitted>
  <study_first_submitted_qc>November 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2007</study_first_posted>
  <last_update_submitted>November 22, 2007</last_update_submitted>
  <last_update_submitted_qc>November 22, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2007</last_update_posted>
  <keyword>Portal hypertension</keyword>
  <keyword>Prevention of rebleeding</keyword>
  <keyword>Complications of cirrhosis</keyword>
  <keyword>Portal hemodynamic</keyword>
  <keyword>Prazosine</keyword>
  <keyword>Nadolol</keyword>
  <keyword>isosorbide mononitrate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

